Clindamycin hydrochloride (CLH) is a clinically important oral antibiotic with wide spectrum of antimicrobial activity that includes gram-positive aerobes (staphylococci, streptococci etc.), most anaerobic bacteria, Chlamydia and certain protozoa. The current study was focused to develop a stabilised clindamycin encapsulated poly lactic acid (PLA)/poly (D,L-lactide-co-glycolide) (PLGA) nano-formulation with better drug bioavailability at molecular level. Various nanoparticle (NPs) formulations of PLA and PLGA loaded with CLH were prepared by solvent evaporation method varying drug: polymer concentration (1:20, 1:10 and 1:5) and characterised (size, encapsulation efficiency, drug loading, scanning electron microscope, differential scanning calorimetry [DSC] and Fourier transform infrared [FTIR] studies). The ratio 1:10 was found to be optimal for a monodispersed and stable nano formulation for both the polymers. NP formulations demonstrated a significant controlled release profile extended up to 144 h (both CLH-PLA and CLH-PLGA). The thermal behaviour (DSC) studies confirmed the molecular dispersion of the drug within the system. The FTIR studies revealed the intactness as well as unaltered structure of drug. The CLH-PLA NPs showed enhanced antimicrobial activity against two pathogenic bacteria Streptococcus faecalis and Bacillus cereus. The results notably suggest that encapsulation of CLH into PLA/PLGA significantly increases the bioavailability of the drug and due to this enhanced drug activity; it can be widely applied for number of therapies.

References

1. 1)
  - 1. Darley, E.S., MacGowan, A.P.: ‘Antibiotic treatment of gram-positive bone and joint infections’, J. Antimicrob. Chemother., 2004, 53, (6), pp. 928–935 (doi: 10.1093/jac/dkh191).
2. 2)
  - 2. Daum, R.S.: ‘Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus‘, N. Eng. J. Med., 2007, 357, (4), pp. 380–390 (doi: 10.1056/NEJMcp070747).
3. 3)
  - 3. Brook, I., Lewis, M.A., Sándor, G.K., et al: ‘Clindamycin in dentistry: more than just effective prophylaxis for endocarditis?’, Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod., 2005, 100, pp. 550–558 (doi: 10.1016/j.tripleo.2005.02.086).
4. 4)
  - 4. Lell, B., Kremsner, P.G.: ‘Clindamycin as an antimalarial drug: review of clinical trials’, Antimicrob. Agents. Chemother., 2002, 46, (8), pp. 2315–2320 (doi: 10.1128/AAC.46.8.2315-2320.2002).
5. 5)
  - 5. Annane, D., Clair, B., Salomon, J.: ‘Managing toxic shock syndrome with antibiotics’, Expert. Opin. Pharmacother., 2004, 5, (8), pp. 1701–1710 (doi: 10.1517/14656566.5.8.1701).
6. 6)
  - 6. Coyle, E.A.: ‘Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections’, Soc. Infect. Dis. Pharm. Pharmacother., 2003, 23, (5), pp. 638–642.
7. 7)
  - 7. Gao, P., Nie, X., Zou, M., et al: ‘Recent advances in materials for extended-release antibiotic delivery system’, J. Antibiot. (Tokyo), 2011, 64, pp. 625–634 (doi: 10.1038/ja.2011.58).
8. 8)
  - 8. Jong, W.H.D., Borm, P.J.A.: ‘Drug delivery and nanoparticles: applications and hazards’, Int. J. Nanomedicine, 2008, 3, (2), pp. 133–149 (doi: 10.2147/IJN.S596).
9. 9)
  - 9. Patel, A., Patel, M., Yang, X., et al: ‘Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles’, Protein Pept. Lett., 2014, 21, (11), pp. 1102–1120 (doi: 10.2174/0929866521666140807114240).
10. 10)
  - 10. Diab, R., Jaafar-Maalej, C., Fessi, H., et al: ‘Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?’, AAPS J., 2012, 14, (4), pp. 688–702 (doi: 10.1208/s12248-012-9377-y).
11. 11)
  - 11. Ulery, B.D., Nair, L.S., Laurencin, C.T.: ‘Biomedical applications of biodegradable polymers’, J. Polym. Sci. B: Polym. Phys., 2011, 49, (12), pp. 832–864 (doi: 10.1002/polb.22259).
12. 12)
  - 12. Pinto-Alphandary, H., Andremont, A., Couvreur, P.: ‘Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications’, Int. J. Antimicrob. Agents, 2000, 13, pp. 155–168 (doi: 10.1016/S0924-8579(99)00121-1).
13. 13)
  - 13. Abdelghany, S.M., Quinn, D.J., Ingram, R.J., et al: ‘Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection’, Int. J. Nanomed., 2012, 7, pp. 4053–4063.
14. 14)
  - 14. Seleem, M.N., Munusamy, P., Ranjan, A., et al: ‘Silica-antibiotic hybrid nanoparticles for targeting intracellular pathogens’, Antimicrob. Agents Chemother., 2009, 53, pp. 4270–4274 (doi: 10.1128/AAC.00815-09).
15. 15)
  - 15. Machado, S.R.P., Evangelista, R.C.: ‘Development and characterization of cefoxitin loaded D, L-PLA nanoparticles’, J. Basic. Appl. Sci., 2010, 31, (3), pp. 193–202.
16. 16)
  - 16. Fawzy, A.E., Salah, M.B.: ‘Spectrophotometric and titrimetric determination of clindamycin hydrochloride in pharmaceutical preparations’, Analyst., 1993, 118, pp. 577–579 (doi: 10.1039/an9931800577).
17. 17)
  - 17. CLSI, Wayne: ‘Clinical and laboratory standards institute methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobicall’, Approve Standard M7-A7, CLSI, seventh ed., PA, USA, 2006.
18. 18)
  - 18. Thomasin, C., Corradin, G., Men, Y., et al: ‘Tetanus toxoid and synthetic malaria antigen containing poly (lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response’, J. Control Release, 1996, 41, pp. 131–145 (doi: 10.1016/0168-3659(96)01363-6).
19. 19)
  - 19. Rosler, A., Vandermeulen, G.W.M., Klok, H.A.: ‘Advanced drug delivery devices via self-assembly of amphiphilic block copolymers’, Adv. Drug Deliv. Rev., 2001, 53, pp. 95–108 (doi: 10.1016/S0169-409X(01)00222-8).
20. 20)
  - 20. Santhi, K., Venkatesh, D.N., Dhanaraj, S.A., et al: ‘Development and In-vitro evaluation of a topical drug delivery system containing Betamethazone loaded ethyl cellulose nanospheres’, Trop. J. Pharm. Res., 2005, 4, (20), pp. 495–500.
21. 21)
  - 21. Ravikumara, N.R., Madhusudhan, B., Nagaraj, T.S., et al: ‘Preparation and evaluation of Nimesulide-loaded ethylcellulose and methylcellulose nanoparticles and microparticles for oral delivery’, J. Biomater. Appl., 2009, 24, pp. 47–63 (doi: 10.1177/0885328209103406).
22. 22)
  - 22. Nayak, B., Panda, A.K., Ray, P.: ‘Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination’, J. Microencapsul., 2009, 26, (2), pp. 154–165 (doi: 10.1080/02652040802211709).
23. 23)
  - 23. McNaught, A.D., Wilkinson, A.: Blackwell Scientific Publications, Oxford. Complied version of Nic, M., Jirat, J., Kosata, B. and Jenkins, A. Definition of electro kinetic potential in ‘IUPAC. Compendium of Chemical Terminology’, 2nd ed. (the ‘Gold Book’). XML on-line corrected version: available at http://goldbook.iupac.org (2006-) ISBN0-9678550-9-8, 1997.
24. 24)
  - 24. Tripathi, A., Gupta, R., Saraf, S.A.: ‘PLGA nanoparticles of anti tubercular drug: drug loading and release studies of a water in-soluble drug’, Int. J. Pharm. Tech. Res., 2010, 2, (3), pp. 2116–2123.
25. 25)
  - 25. Gander, B., Johansen, P., Nam-trân, H., et al: ‘Thermodynamic approach to protein microencapsulation into poly (D,L-lactide) by spray drying’, Int. J. Pharm., 1996, 129, pp. 51–61 (doi: 10.1016/0378-5173(95)04240-7).
26. 26)
  - 26. Prior, S., Gamazo, C., Irache, J.M., et al: ‘Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections’, Int. J.Pharm., 2000, 16, pp. 115–125 (doi: 10.1016/S0378-5173(99)00448-2).
27. 27)
  - 27. Yasemin, C., Robineau, C., Çapan, Y.: ‘Etodolac loaded Poly (Lactide Co-Glycolide) nanoparticles: formulation and in vitro characterization’, Hacettepe Univ. J Faculty Pharm., 2009, 29, (2), pp. 105–114.
28. 28)
  - 28. Kashi, T.S., Eskandarion, S., Esfandyari-Manesh, M., et al: ‘Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method’, Int. J. Nanomedicine., 2012, 7, pp. 221–234.
29. 29)
  - 29. Rawat, A., Majumder, Q.H., Ahsan, F.: ‘Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation’, J. Control. Release, 2008, 128, pp. 224–232 (doi: 10.1016/j.jconrel.2008.03.013).
30. 30)
  - 30. Dubernet, C.: ‘Thermoanalysis of microspheres’, Thermo. Chim. Acta., 1995, 248, pp. 259–269 (doi: 10.1016/0040-6031(94)01947-F).
31. 31)
  - 31. Ford, J.L., Timmins, P.: ‘Pharmaceutical thermal analysis’ (John Wiley & Sons, Chichester, 1989).
32. 32)
  - 32. Narladkar, A., Balnois, E., Vignaud, G., et al: ‘Difference in glass transition behavior between semi crystalline and amorphous poly (lactic acid) thin films’, Macromol. Symp., 2008, 273, pp. 146–152 (doi: 10.1002/masy.200851321).
33. 33)
  - 33. Hariharan, M., Price, J.C.: ‘Solvent, emulsifier and drug concentration factors in poly-(D,L-Lactic acid) microspheres containing hexamethylmelamine’, J. Microencapsul., 2002, 19, (1), pp. 95–109 (doi: 10.1080/02652040110081398).
34. 34)
  - 34. Jordan, J., Jacob, K.I., Tannenbaum, R., et al: ‘Experimental trends in polymer nanocomposites: A review’, Mater. Sci. Eng., 2005, 393, pp. 1–11 (doi: 10.1016/j.msea.2004.09.044).
35. 35)
  - 35. Devi, T.S.R., Gayathri, S.: ‘FTIR and FT-Raman spectral analysis of Paclitaxel drugs’, Int. J. Pharmaceut. Sci. Rev. Res., 2010, 2, (2), pp. 106–110.
36. 36)
  - 36. Azhdarzadeh, M., Lotfipour, F., Zakeri-Milani, P., et al: ‘Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram positive bacteria’, Adv. Pharmaceut. Bull., 2012, 2, (1), pp. 17–24.

Enhanced efficacy of clindamycin hydrochloride encapsulated in PLA/PLGA based nanoparticle system for oral delivery

Enhanced efficacy of clindamycin hydrochloride encapsulated in PLA/PLGA based nanoparticle system for oral delivery

Buy article PDF

Buy Knowledge Pack

Thank you

References

Related content